The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Novel Approaches to Drug Discovery for Parkinson's Disease, 2009Optimization of Alpha-synuclein 5'UTR Directed Translation Blockers as Novel Drugs for Parkinson's Disease
Objective/Rationale:
Posiphen is a well-tolerated translation blocker of the Parkinson’s disease causative protein alpha-synuclein (SNCA) via the 5’untranslated region (5’UTR) in its mRNA. Our goal is... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2009Cerium Oxide Nanoparticles in Treatment of Parkinson's Disease
Objective/Rationale:
Nanotechnology and nanomedicine hold potential to advance medical treatment through construction of materials with enhanced biological effects, at the atomic scale. By... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2009Novel JNK Inhibitors as Therapeutic Agents for Parkinson's Disease
Objective/Rationale:
Our objective is to test the in vivo pharmacokinetic profile, mode of action and efficacy of two novel and highly selective JNK inhibitors in the MPTP (1-methyl-4-phenyl-1,2,3,6... -
Program-non-specific Funding, 2009LRRK2 Variation in Parkinson's Disease
Objective/Rationale:
Over the last decade genetic causes of Parkinson’s disease have given great insights into the pathways and mechanisms that play a role in the disease. The discovery of common... -
Program-non-specific Funding, 2009Delivery of Kinase-Modified LRRK2 to Dopaminergic Neurons Using High-Capacity Viral Vectors
Promising Outcomes of Original Grant:
Mutations in LRRK2 are the most common known cause of PD, and LRRK2 demonstrates kinase-dependent neurotoxicity in vitro but these results have not been confirmed... -
Program-non-specific Funding, 2009Immunology and bio activity of regulated rAAV1-GDNF in pre-clinical models of PD
Objective/Rationale:
Clinical trials with a trophic factor called GDNF, where GDNF is injected directly in the brain by pumps, have not been completely successful. Many scientists believe that the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.